Enzyme-linked immunosorbent assays (ELISAs) showed that TIMP-2 concentrations in the serum of patients with NSCLC were significantly lower in patients with stage II/III cancer than in patients with stage I cancer (Fig. 5A). This evidence concerns the gene TIMP2 and cancer.